BioPharma Dive November 8, 2023
The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk’s competing drug Wegovy.
The Food and Drug Administration on Wednesday approved a powerful new medicine for weight loss, clearing Eli Lilly’s Zepbound for adults with obesity or who are overweight and have at least one related health condition.
The drug, which was already available to treat Type 2 diabetes under the brand name Mounjaro, is one of a class of medicines known as GLP-1 agonists that have revolutionized the treatment of obesity. Demand for these drugs is already sky-high and outstripping the ability of their makers, Lilly and rival Novo Nordisk, to supply them.
Lilly will sell Zepbound for...
Today's Sponsors
Today's Sponsor